USPTO 2015–2025 USPTO PatentsView US Corporation

Sunesis Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 23 granted patents across 14 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company

The verdict

According to USPTO PatentsView, Sunesis ranks #13,177 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 14 technology areas.

#13,177
of 49,997 US assignees by volume
47th percentile
by Innovation Score (34.3/100)
16.8
avg claims per patent
-85%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13177 · US Corporation #13,177 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 23 grants
  • MID-PACK #13,177/49,997
  • PHOTO-FINISH Spacelabs Healthcare…
  • CPC-FOCUS C07D · 14 areas
  • INNOV-THIN 34.3/100
  • CLAIMS-RICH 16.8 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -85% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Spacelabs Healthcare L.L.C. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sunesis’s 34.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Sunesis

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Sunesis's Innovation Score is 34.3/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Sunesis?

Each dot is one of Sunesis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sunesis’s own 16.8 claims/patent is at or below the 18.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Sunesis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 22.922.92323.1 0510152025 Granted patents (volume) Avg claims / patent Spacelabs Healthcare L.L.C. - 23, 18.17Spacelabs Healthc…SpiderOak, Inc. - 23, 21.04SpideroakStudy Social, Inc. - 23, 19.87Study SocialSun Nuclear Corporation - 23, 15.96Sun NuclearSweet Darling Sales, Inc. - 23, 2.22Sweet Darling Sal…Synexis LLC - 23, 14.57SynexisSyntiant Corp. - 23, 18.35SyntiantSysdig, Inc. - 23, 19.35SysdigSunesis Pharmaceuticals, Inc. - 23, 16.78Sunesis Pharmaceu…
Sunesis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sunesis's grants concentrate

Sunesis Pharmaceuticals, Inc. is a focused PatentsView assignee: 14 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (7 grants) versus a trough of 1 in 2015. By volume, Sunesis sits between Spacelabs Healthcare L.L.C. and Sysdig, Inc..

Who files at Sunesis's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Sunesis holds 23 patents at rank #13,171, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Sunesis

By rank, the assignees closest to #13,171 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Sunesis's primary technology class.

Sunesis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 201520162017201820202021 1
USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Sunesis Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 4.3%
2016 5 21.7%
2017 7 30.4%
2018 7 30.4%
2020 2 8.7%
2021 1 4.3%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Sunesis Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Sunesis Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #13,177 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Sunesis Pharmaceuticals, Inc. against Spacelabs Healthcare L.L.C., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 34.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.